Annual results moved from KRW 81.6 billion in revenue and KRW 24.3 billion in operating profit in 2022 to KRW 174.9 billion and KRW 57 billion in 2024, the largest year in 2022-2025. Revenue rose 41.5% to KRW 115.5 billion in 2023 and operating profit rose 26.9% to KRW 30.8 billion.
In 2024, revenue rose 51.5% and operating profit rose 84.7%. In 2025, revenue fell 6.1% to KRW 164.2 billion, operating profit fell 18.6% to KRW 46.4 billion, and controlling-shareholder net income fell 18.0% to KRW 38.1 billion. Operating margin was 29.8% in 2022, 26.7% in 2023, 32.6% in 2024 and 28.2% in 2025.
Sangsangin Securities said the U.S. wound-dressing inventory adjustment was completed in 2025, a factor behind the decline.
Quarterly results show a trough in Q4 2025, with revenue of KRW 33.4 billion (down 17.9% from the prior quarter), operating profit of KRW 4.02 billion (down 66.9%) and controlling-shareholder net income of KRW 3.06 billion (down 73.0%).
Q1 2026 revenue was KRW 45.1 billion, operating profit KRW 18.3 billion and controlling-shareholder net income KRW 16.4 billion. Q2 2026 revenue was KRW 56 billion, operating profit KRW 25 billion and controlling-shareholder net income KRW 19.9 billion.
Q3 2026 revenue was KRW 52.5 billion (down 6.2% from the prior quarter, up 29.2% year on year), operating profit KRW 21.7 billion (down 13.0% quarter on quarter, up 78.9% year on year) and controlling-shareholder net income KRW 12.9 billion (up 14.0% year on year).
Controlling-shareholder net income for the last four quarters totaled KRW 52.4 billion. On margins, Hana Securities said a return to two- and three-shift operations lowered fixed-cost burdens. Exchange rates matter because export sales are recorded at the rate on the shipping date.
At the end of 2025, total equity was KRW 201.2 billion, total liabilities KRW 15.9 billion and the debt ratio 7.9%.